Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents

Journal of Diabetes and its Complications

Volumn 23, Issue 6, 2009, Pages 427-433

  Anselmino, Matteo ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cardiovascular disease; Diabetes mellitus; Morbidity; Mortality; Oral glucose lowering agents; Treatment

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG FATALITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RESPONSE; INSULIN SYNTHESIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; MORBIDITY;

EID: 70350499471     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2008.07.003     Document Type: Review

References (48)

1. Abbasi F., Kamath V., Rizvi A.A., Carantoni M., Chen Y.D., and Reaven G.M. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care 20 (1997) 1863-1869
2. Anselmino M., Bartnik M., Malmberg K., and Ryden L. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor-a report from the Euro Heart Survey on diabetes and the heart. European Journal of Cardiovascular Prevention and Rehabilitation 14 (2007) 28-36
3. Anselmino M., Malmberg K., Öhrvik J., and Ryden L. Evidence-based medication and revascularization: Powerful tools in the management of patients with diabetes and coronary artery disease. A report from the Euro Heart Survey on diabetes and the heart. European Journal of Cardiovascular Prevention and Rehabilitation 15 (2008) 216-223
4. Anselmino M., Öhrvik J., Malmberg K., Standl E., and Rydén L. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus. A report from the Euro Heart Survey on diabetes and the heart. European Heart Journal 29 (2008) 177-184
5. Belcher G., Lambert C., Goh K.L., Edwards G., and Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. International Journal of Clinical Practice 58 (2004) 833-837
6. Bressler R., and Johnson D.G. Oral antidiabetic drug use in the elderly. Drugs & Aging 9 (1996) 418-437
7. Breuer H.W. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. International Journal of Clinical Pharmacology and Therapeutics 41 (2003) 421-440
8. Chiasson J.L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocrine Practice 12 Suppl. 1 (2006) 25-30
9. Cusi K., Consoli A., and DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 81 (1996) 4059-4067
10. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. New England Journal of Medicine 333 (1995) 541-549
11. Dimitriadis G., Tessari P., Go V., and Gerich J. Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal man. Metabolism 31 (1982) 841-843
12. Dinneen S., Gerich J., and Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. New England Journal of Medicine 327 (1992) 707-713
13. Dunn C.J., and Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49 (1995) 721-749
14. Evans J.M., Ogston S.A., Emslie-Smith A., and Morris A.D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (2006) 930-936
15. Fisman E.Z., Tenenbaum A., Boyko V., Benderly M., Adler Y., Friedensohn A., et al. Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clinical Cardiology 24 (2001) 151-158
16. Fisman E.Z., Tenenbaum A., Motro M., and Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz 29 (2004) 290-298
17. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 348 (2003) 383-393
18. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368 (2006) 1096-1105
19. Ginsberg H., Plutzky J., and Sobel B.E. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering. Journal of Cardiovascular Risk 6 (1999) 337-346
20. Gulliford M., and Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: Cohort study. Diabetes/Metabolism Research and Reviews 20 (2004) 239-245
21. Herrmann B.L., Erbel R., Janssen O.E., and Mann K. Cardiovascular effects of oral hypoglycemie drugs. Herz 29 (2004) 510-518
22. Hu G., Eriksson J., Barengo N.C., Lakka T.A., Valle T.T., Nissinen A., et al. Occupational, commuting, and leisure-time physical activity in relation to total and cardiovascular mortality among Finnish subjects with type 2 diabetes. Circulation 110 (2004) 666-673
23. Inzucchi S.E., Masoudi F.A., Wang Y., Kosiborod M., Foody J.M., Setaro J.F., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
24. Johnson J.A., Simpson S.H., Toth E.L., and Majumdar S.R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabetic Medicine 22 (2005) 497-502
25. Kendall D.M., Kim D., and Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: A review of emerging therapies for type 2 diabetes. Diabetes Technology & Therapeutics 8 (2006) 385-396
26. Krall R.L. Cardiovascular safety of rosiglitazone. Lancet 369 (2007) 1995-1996
27. Mannucci E., Monami M., Masotti G., and Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes/Metabolism Research and Reviews 20 (2004) 44-47
28. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. Journal of the American Medical Association 296 (2006) 2572-2581
29. Medical Management of Type 2 Diabetes. 4th ed (1998), American Diabetes Association, Alexandria, VA 1-139
30. Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes Suppl 19 (1970) 789-830
31. Mellbin L., Malmberg K., Norhammar A., Wedel H., and Rydén L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction. A report from the DIGAMI 2 trial. European Heart Journal 29 (2008) 166-176
32. Monami M., Luzzi C., Lamanna C., Chiasserini V., Addante F., Desideri C.M., et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes/Metabolism Research and Reviews 22 (2006) 477-482
33. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356 (2007) 2457-2471
34. Olsson J., Lindberg G., Gottsater M., Lindwall K., Sjostrand A., Tisell A., et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: A population-based observational study. Diabetologia 43 (2000) 558-560
35. O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: The gathering storm. British Medical Journal 314 (1997) 955-959
36. Panunti B., Kunhiraman B., and Fonseca V. The impact of antidiabetic therapies on cardiovascular disease. Current Atherosclerosis Reports 7 (2005) 50-57
37. Pastors J.G., Warshaw H., Daly A., Franz M., and Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 25 (2002) 608-613
38. Perriello G., Misericordia P., Volpi E., Santucci A., Santucci C., Ferrannini E., et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43 (1994) 920-928
39. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
40. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. Journal of Diabetes and Its Complications 16 1 (2002) 123-132
41. Rosiglitazone: Seeking a balanced perspective. Lancet 369 (2007) 1834
42. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal 28 (2007) 88-136
43. Scheen A.J., and Lefebvre P.J. Proactive study: Secondary cardiovascular prevention with pioglitazone in type 2 diabetic patients. Revue Medicale de Liege 60 (2005) 896-901
44. Simpson S.H., Majumdar S.R., Tsuyuki R.T., Eurich D.T., and Johnson J.A. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: A population-based cohort study. Canadian Medical Association Journal 174 (2006) 169-174
45. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1 (2004) S15-S35
46. Stonehouse A.H., Holcombe J.H., and Kendall D.M. Management of type 2 diabetes: The role of incretin mimetics. Expert Opinion on Pharmacotherapy 7 (2006) 2095-2105
47. Taylor S.I. Deconstructing type 2 diabetes. Cell 97 (1999) 9-12
48. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865